Point72 Asset Management Reports 0.2% Stake in C4 Therapeutics, Inc. (CCCC)

On May 15, 2026, Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen filed a Schedule 13G/A with the SEC, reporting a combined beneficial ownership of 169,096 shares of Common Stock in C4 Therapeutics, Inc. (CCCC). This position represents approximately 0.2% of the company's outstanding shares as of March 31, 2026. The filing indicates an increase from a previously reported 0.0% ownership stake. Point72 Asset Management maintains investment and voting power over the shares held by its managed investment funds, while Point72 Capital Advisors, Inc. serves as the general partner and Steven A. Cohen controls both entities. Several sub-advisors, including Cubist Systematic Strategies, LLC and various regional Point72 entities, also provide sub-advisory services regarding these holdings. The reporting persons certified that the acquisition was made in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer.